Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Should l Buy ?
Source: Newsfilter
Financial Overview: Organovo Holdings reported a preliminary cash balance of approximately $11.3 million for the fiscal year ending March 31, 2025, with net cash utilization in the fourth quarter estimated between $2.0 - $2.2 million.
Nasdaq Compliance and Future Milestones: The company expects to meet Nasdaq listing requirements as its stock has been trading above the $1.00 minimum bid price since March 21, 2025, and anticipates receiving a $5 million milestone payment related to a Phase 2 clinical trial for an FXR agonist within the next year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
